EP0900081A1 - Inhibiteurs de farnesyl-proteine transferase - Google Patents
Inhibiteurs de farnesyl-proteine transferaseInfo
- Publication number
- EP0900081A1 EP0900081A1 EP97917604A EP97917604A EP0900081A1 EP 0900081 A1 EP0900081 A1 EP 0900081A1 EP 97917604 A EP97917604 A EP 97917604A EP 97917604 A EP97917604 A EP 97917604A EP 0900081 A1 EP0900081 A1 EP 0900081A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substituted
- alkyl
- aryl
- unsubstituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- R l a and R ib are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, RlOO-, Rl lS(0) m -, R 10 C(O)NRl0-, (RlO)2NC(0)-, R l ⁇ 2N-C(NRlO)-, CN, N02, R 10 C(O)-, N3, -N(RlO)2, O ⁇ RH OC(O)NR 10-, c) unsubstituted or substituted C1 -C6 alkyl wherein the substitutent on the substituted -C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, Rl°0-, R l lS(0) m -
- the substituted Cl -8 alkyl, substituted C3-6 cycloalkyl, substituted aroyl, substituted aryl, substituted heteroaroyl, substituted arylsulfonyl, substituted heteroarylsulfonyl and substituted heterocycle include moieties containing from 1 to 3 substitutents in addition to the point of attachment to the rest of the compound.
- an unsubstituted or substituted group the group selected from Cl-8 alkyl, C2-8 alkenyl and C2-8 alkynyl; wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) Cj -4 alkyl, d) halogen,
- s is 0.
- the compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment.
- a component of NF-1 is a benign proliferative disorder.
- the instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. Science, 256: 1331 - 1333 ( 1992).
- the compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1 :541 -545(1995).
- Step D Preparation of (S)-6-/?-butyl-l-[l -(4-cyanobenzyl)-5- imidazolylmethyl]-4-(2,3-dimethylphenyl)-2-piperazinone hydrochloride
- the titled compound is prepared from the product of Step
- the cell line used in this assay is a v-ras line derived from either Ratl or NIH3T3 cells, which expressed viral Ha-ras p21.
- the assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51 :712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1 %).
- Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x 10 4 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer (0.6%). Both layers contain 0.1 % methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay).
- the cells are fed twice weekly with 0.5 ml of medium A containing 0.1 % methanol or the concentration of the instant compound.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1479296P | 1996-04-03 | 1996-04-03 | |
US14792P | 1996-04-03 | ||
GBGB9610338.7A GB9610338D0 (en) | 1996-05-17 | 1996-05-17 | Inhibitors of farnesyl-protein transferase |
GB9610338 | 1996-05-17 | ||
PCT/US1997/004750 WO1997036591A1 (fr) | 1996-04-03 | 1997-03-27 | Inhibiteurs de farnesyl-proteine transferase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0900081A1 true EP0900081A1 (fr) | 1999-03-10 |
EP0900081A4 EP0900081A4 (fr) | 2002-01-09 |
Family
ID=26309349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97917604A Withdrawn EP0900081A4 (fr) | 1996-04-03 | 1997-03-27 | Inhibiteurs de farnesyl-proteine transferase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0900081A4 (fr) |
JP (1) | JP2001518067A (fr) |
AU (1) | AU707347B2 (fr) |
CA (1) | CA2250587A1 (fr) |
WO (1) | WO1997036591A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2336475A1 (fr) | 1998-07-02 | 2000-01-13 | Christopher J. Dinsmore | Inhibiteurs de prenyl-proteine transferase |
SI1940786T1 (sl) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Ltd | Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C |
WO2010114896A1 (fr) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Composés indolo-pyridinone substitués |
CA2801074A1 (fr) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Inhibiteurs du transporteur 1 de la glycine, procedes de fabrication associes, et utilisations associees |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA983495A (en) * | 1972-10-11 | 1976-02-10 | Gilbert Regnier | Procede de preparation de derives du benzodioxole |
US4598079A (en) * | 1981-08-20 | 1986-07-01 | Cassella Aktiengesellschaft | 2-(aryl substitued)piperazinones and nootropic compositions based thereon |
WO1993021186A1 (fr) * | 1992-04-13 | 1993-10-28 | Fujisawa Pharmaceutical Co., Ltd. | 3-pyrrolidinylthio-carbapenemes substitues, utilises comme agents antimicrobiens |
WO1995000497A1 (fr) * | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibiteurs de farnesyle-proteine transferase |
US5382584A (en) * | 1992-07-31 | 1995-01-17 | Bristol-Myers Squibb Company | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles |
EP0670314A1 (fr) * | 1993-09-22 | 1995-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de la farnesyl-transferase |
WO1996030343A1 (fr) * | 1995-03-29 | 1996-10-03 | Merck & Co., Inc. | Inhibiteurs de farnesyl-proteine transferase |
WO1996037204A1 (fr) * | 1995-05-24 | 1996-11-28 | Merck & Co., Inc. | Inhibiteurs de la farnesyle-proteine transferase |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915981A (en) * | 1973-03-16 | 1975-10-28 | Yoshitomi Pharmaceutical | 1-{8 2-(2-Chlorobenzoyl)-4-nitrophenyl{9 -2-(diethylaminomethyl)-imidazole |
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
WO1996016057A1 (fr) * | 1994-11-23 | 1996-05-30 | Neurogen Corporation | Certains derives d'aminoethyl imidazole et pyrrole substitues en 1; nouveaux ligands specifiques d'un sous-type de recepteur dopaminergique |
US5478934A (en) * | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
-
1997
- 1997-03-27 JP JP53535797A patent/JP2001518067A/ja active Pending
- 1997-03-27 WO PCT/US1997/004750 patent/WO1997036591A1/fr not_active Application Discontinuation
- 1997-03-27 EP EP97917604A patent/EP0900081A4/fr not_active Withdrawn
- 1997-03-27 AU AU25879/97A patent/AU707347B2/en not_active Ceased
- 1997-03-27 CA CA002250587A patent/CA2250587A1/fr not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA983495A (en) * | 1972-10-11 | 1976-02-10 | Gilbert Regnier | Procede de preparation de derives du benzodioxole |
US4598079A (en) * | 1981-08-20 | 1986-07-01 | Cassella Aktiengesellschaft | 2-(aryl substitued)piperazinones and nootropic compositions based thereon |
WO1993021186A1 (fr) * | 1992-04-13 | 1993-10-28 | Fujisawa Pharmaceutical Co., Ltd. | 3-pyrrolidinylthio-carbapenemes substitues, utilises comme agents antimicrobiens |
US5382584A (en) * | 1992-07-31 | 1995-01-17 | Bristol-Myers Squibb Company | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles |
WO1995000497A1 (fr) * | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibiteurs de farnesyle-proteine transferase |
EP0670314A1 (fr) * | 1993-09-22 | 1995-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de la farnesyl-transferase |
WO1996030343A1 (fr) * | 1995-03-29 | 1996-10-03 | Merck & Co., Inc. | Inhibiteurs de farnesyl-proteine transferase |
WO1996037204A1 (fr) * | 1995-05-24 | 1996-11-28 | Merck & Co., Inc. | Inhibiteurs de la farnesyle-proteine transferase |
Non-Patent Citations (1)
Title |
---|
See also references of WO9736591A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1997036591A1 (fr) | 1997-10-09 |
EP0900081A4 (fr) | 2002-01-09 |
CA2250587A1 (fr) | 1997-10-09 |
JP2001518067A (ja) | 2001-10-09 |
AU2587997A (en) | 1997-10-22 |
AU707347B2 (en) | 1999-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU716338B2 (en) | Inhibitors of farnesyl-protein transferase | |
US5919785A (en) | Inhibitors of farnesyl-protein transferase | |
US6066738A (en) | Inhibitors of farnesyl-protein transferase | |
US5914341A (en) | Inhibitors of farnesyl-protein transferase | |
US5968965A (en) | Inhibitors of farnesyl-protein transferase | |
US5885995A (en) | Inhibitors of farnesyl-protein transferase | |
AU715603B2 (en) | Inhibitors of farnesyl-protein transferase | |
US5925651A (en) | Inhibitors of farnesyl-protein transferase | |
AU715667B2 (en) | Inhibitors of farnesyl-protein transferase | |
US5780492A (en) | Inhibitors of farnesyl-protein transferase | |
EP0897303A1 (fr) | Inhibiteurs de farnesyl-proteine transferase | |
WO1997027752A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
AU706495B2 (en) | Inhibitors of farnesyl-protein transferase | |
WO1997036886A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
AU707416B2 (en) | Inhibitors of farnesyl-protein transferase | |
EP0891352A1 (fr) | Inhibiteurs de la farnesyl-proteine transferase | |
EP0891353A1 (fr) | Inhibiteurs de farnesyle-proteine transferase | |
US6028201A (en) | Inhibitors of farnesyl-protein transferase | |
AU703988B2 (en) | Inhibitors of farnesyl-protein transferase | |
AU707347B2 (en) | Inhibitors of farnesyl-protein transferase | |
US5972942A (en) | Inhibitors of farnesyl-protein transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981103 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/495 A, 7C 07D 403/06 B, 7C 07D 401/06 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20011123 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020211 |